(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.65% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Merck & Co's revenue in 2026 is $65,768,000,000.On average, 31 Wall Street analysts forecast MRK's revenue for 2026 to be $166,253,760,671,310, with the lowest MRK revenue forecast at $159,688,967,376,240, and the highest MRK revenue forecast at $174,214,004,760,855. On average, 30 Wall Street analysts forecast MRK's revenue for 2027 to be $174,940,133,138,865, with the lowest MRK revenue forecast at $164,813,853,037,365, and the highest MRK revenue forecast at $187,267,026,794,130.
In 2028, MRK is forecast to generate $186,812,579,101,770 in revenue, with the lowest revenue forecast at $173,989,250,739,090 and the highest revenue forecast at $206,062,390,592,280.